The 20th JSSX workshop
Date：April 13-14th, 2006
Venue： Showa University (1-5-8, Hatanodai, Shinagawa-ku, Tokyo)
Main topic： Pharmacokinetic technologies to break through the bottleneck of drug discovery and development
Chairperson： Tetsuo Miwa (Takeda Pharmaceutical Company Limited)
Organizer： The Japanese Society for the Study of Xenobiotics

April 13th 8:50-17:00
8:50-9:00 Opening Remarks

Keynote lecture
9:00-9:50 Drug discovery in the 3rd millennium
Alex Matter (Institute for Tropical Diseases of the Novartis Foundation)

Session 1 Discovery ADME/Tox screening

9:50-10:20 Impact of ADME/Physicochemistry screening on drug discovery
Toshio Teramura (Astellas Pharma Inc)

10:20-10:50 Integrated experimental ADME/Tox screening and pharmacokinetic simulation
Darwin Cheney (Cyprotex, UK)

10:50-11:00 Break

11:00-11:30 Early ADME/Tox profiling during discovery research:
Streamlined, high throughput methods for data generation and data evaluation
Daniel Kassel (Takeda San Diego)

11:30-12:00 Utility of in silico ADMET from the viewpoint of a medicinal chemist
Yukio Tada (Taiho Pharmaceutical Co Ltd)

12:00-13:30 Lunch

Session 2 From preclinical ADME to clinical pharmacokinetics
(integration of experimental data and mathematical model)

13:30-14:00 Establishment of a BBB permeability assessment: From immortalized cell line to transporter and proteomics
Tetsuya Terasaki (Tohoku University)

14:00-14:30 Practical simulations vs accurate predictions: Best use of the known-knowns to discover unknown-unknowns
Amin Rostami-Hodgegan (Sheffield University)

14:30-15:00 Establishment of a drug-drug interaction database with a simulating function.
Motohiro Kato (Chugai Pharmaceutical Co Ltd)

15:00-15:20 Break

15:20-15:50 System Pharmacology: Innovative paths to better medicines
Michael C Cerio (BG Medicine)

15:50-16:20 Clinical trial simulation based on PK/PD: Scope and limitation
Susumu Nakade (Ono Pharmaceutical Co Ltd)

16:20-17:10 The scientific basis of proof of concept studies
Paul Rolan (University of Adelaide)

17:30-19:30 Banquet

April 14th 8:50-17:00

Keynote lecture

9:00-9:50 Drug discovery and development using PET
Hideo Saji (Kyoto University)

Session 1 PK/PD using in vivo imaging technologies

9:50-10:20 Research and development using PET: Results and future
Shintaro Nishimura (Astellas Pharma Inc)

10:20-10:30 Break


10:30-11:00 Imaging of drug target molecule using PET
Tetsuya Suhara (National Institute of Radiological Science)

11:00-11:30 Non-invasive PK/PD analysis using MRI
Akira Nakatani (Nihon Mediphysics)

11:30-13:00 Lunch

Special lecture

13:00-13:50 Essential qualifications for clinical implementation of the personalized medicine
Naoyuki Kamatani (Tokyo Women’s Medical University)

Session 2 Facilitation of clinical trial

13:50-14:40 Human Phase 0 microdosing studies - Results of the CREAM trial
Colin Garner (Xceleron Ltd)

14:40-15:00 Break

15:00-15:50 CYP3A4 and CYP3A5:Their clinical importance and assessment of function
Kenneth Thummel（University of Washington）

15:50-16:20 Activity of IYAKUHIN KAIHATSUSIENKIKOU (Drug Development Supporting Organization)
Masaaki Takanaka（Showa University）

16:20 Closing Remarks